Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodyspl...
Shattuck Labs, Inc. (STTK)
Company Research
Source: GlobeNewswire
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS cohort – – Shattuck to host conference call and webcast today, June 14, 2024 at 7:30 a.m. ET – AUSTIN, TX & DURHAM, NC, June 14, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion pro
Show less
Read more
Impact Snapshot
Event Time:
STTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STTK alerts
High impacting Shattuck Labs, Inc. news events
Weekly update
A roundup of the hottest topics
STTK
News
- Shattuck Labs, Inc. (NASDAQ: STTK) had its price target lowered by analysts at HC Wainwright from $28.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Hold For Now: Shattuck Labs' SL-172154 Potential In Early Trials [Seeking Alpha]Seeking Alpha
- Shattuck Labs, Inc. (NASDAQ: STTK) had its price target lowered by analysts at Citigroup Inc. from $10.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Shattuck Labs, Inc. (NASDAQ: STTK) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
- Shattuck (STTK) Announces Positive Interim Data on Cancer Drug [Yahoo! Finance]Yahoo! Finance
STTK
Earnings
- 2/29/24 - Beat
STTK
Sec Filings
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- STTK's page on the SEC website